Biotech
Isomorphic Labs Raises $2B to Prove AI Can Compress Drug Discovery Timelines
Google DeepMind's spinout secures what could be the largest AI-drug discovery financing ever, but delayed clinical trials test whether algorithms can match biology's pace.
Isomorphic Labs Enters Human Trials With AI-Designed Drugs, Testing Industry’s $3 Billion Bet
DeepMind spinoff's 2026 clinical trials mark first major test of whether machine learning can genuinely reduce drug failure rates beyond early-stage screening.
Eli Lilly’s $2.75 Billion Insilico Deal Marks Enterprise AI’s Shift From Hype to Production
Big Pharma's largest generative AI partnership validates vertical specialization over generalist models—and signals that geopolitics won't block deals where ROI is measurable.
Japan Approves World’s First iPSC Therapies, Reshaping Global Biotech Competition
Commercial authorization for Cuorips and Sumitomo Pharma products validates 20-year development timeline and accelerates regulatory pathways across Asia-Pacific as U.S. and EU lag.
Moderna Settles $2.25 Billion Patent Dispute, Shares Jump 10% on Legal Clarity
The biotech resolves a long-running lipid nanoparticle infringement case with Arbutus and Genevant, clearing a path for its post-COVID vaccine portfolio.